← Back to Clinical Trials
Recruiting NCT06602648

NCT06602648 MELCAYA - Novel Health Care Strategies for Melanoma in Children, Adolescents, and Young Adults - Work Package 3 (WP3)

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06602648
Status Recruiting
Phase
Sponsor University of Florence
Condition Melanoma of Skin
Study Type OBSERVATIONAL
Enrollment 100 participants
Start Date 2024-04-17
Primary Completion 2026-11

Trial Parameters

Condition Melanoma of Skin
Sponsor University of Florence
Study Type OBSERVATIONAL
Phase N/A
Enrollment 100
Sex ALL
Min Age N/A
Max Age 30 Years
Start Date 2024-04-17
Completion 2026-11

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

The aim of this study is to investigate a type of skin cancer, also known as melanoma, in children, adolescents, and young adults, who will be referred to as CAYA patients in this project. The need for this study arises because this disease, in CAYA patients, is still poorly understood due to its rarity in individuals under 30 years old. This often leads to difficulties in assessing its severity and, consequently, in deciding on the necessary treatments to ensure the patient\'s recovery. The goal of this study is to examine melanoma in CAYA patients in order to gather the information needed to provide better diagnoses for affected patients and, as a result, select appropriate treatments to fight the disease and promote the patient\'s full recovery. Additionally, the data collected will be used to create a Pan-European online platform that will allow doctors across the European Union to consult the obtained data and collaborate on particularly complex melanoma cases, always with the aim of ensuring the patient\'s full recovery in the shortest possible time.

Eligibility Criteria

Inclusion Criteria: * adolescent and childhood patients (\< 20 years) or young adults (\< 30 years) * histologically confirmed diagnosis of melanoma or intermediate/ambiguous melanocytic neoplasm (i.e., melanocytomas, SAMPUS, IAMPUS and MELTUMP according to WHO classification) Exclusion criteria: * adult patients (\> 30 years of age) * patients without histologically confirmed diagnosis of melanoma or intermediate/ambiguous melanocytic neoplasm

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology